ZIOPHARM Oncology Inc (ZIOP) had a rough trading day for Friday May 19 as shares tumbled 5.03%, or a loss of $-0.37 per share, to close at $6.99. After opening the day at $7.31, shares of ZIOPHARM Oncology Inc traded as high as $7.55 and as low as $6.97. Volume was 1.43 million shares over 4,991 trades, against an average daily volume of 1.45 million shares and a total float of 132.38 million.
As a result of the decline, ZIOPHARM Oncology Inc now has a market cap of $925.35 million. In the last year, shares of ZIOPHARM Oncology Inc have traded between a range of $7.99 and $4.45, and its 50-day SMA is currently $6.75 and 200-day SMA is $6.09.
ZIOPHARM Oncology Inc is a biopharmaceutical company. The company is engaged in the acquiring, developing and commercializing portfolio of cancer therapies that can address unmet medical needs through synthetic biology.
ZIOPHARM Oncology Inc is based out of Boston, MA and has some 36 employees. Its CEO is .
ZIOPHARM Oncology Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
To get more information on ZIOPHARM Oncology Inc and to follow the company’s latest updates, you can visit the company’s profile page here: ZIOP’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.